Cargando…

The role of proton beam therapy in the management of elderly breast cancer patients

Breast cancer is the most common noncutaneous malignancy in women. The prevalence increases with age such that nearly 7% of women in the United States over age 70 will be diagnosed with breast cancer. Radiation therapy (RT) is a standard component of the treatment course for women of all ages with b...

Descripción completa

Detalles Bibliográficos
Autores principales: Rich, Benjamin J., Asher, David, Giap, Bosco, Giap, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798667/
https://www.ncbi.nlm.nih.gov/pubmed/35117960
http://dx.doi.org/10.21037/tcr.2019.07.40
_version_ 1784641864424488960
author Rich, Benjamin J.
Asher, David
Giap, Bosco
Giap, Huan
author_facet Rich, Benjamin J.
Asher, David
Giap, Bosco
Giap, Huan
author_sort Rich, Benjamin J.
collection PubMed
description Breast cancer is the most common noncutaneous malignancy in women. The prevalence increases with age such that nearly 7% of women in the United States over age 70 will be diagnosed with breast cancer. Radiation therapy (RT) is a standard component of the treatment course for women of all ages with breast cancer. RT is commonly encountered in the adjuvant setting for women with nonmetastatic disease, but also works for disease palliation in women with metastatic or recurrent disease. Different techniques for delivering RT for breast cancer include whole breast irradiation (WBI), accelerated partial-breast irradiation (APBI), and chest wall irradiation. Although these techniques often employ external beam radiation therapy (EBRT) delivered with photons, proton beam radiation therapy (PBRT) may also be used for each of these methods. Dosimetric breast cancer studies demonstrate clinical benefits of PBRT compared to photon EBRT. PBRT reduces the radiation dose delivered to the heart, particularly in women with left-sided breast cancer. This may subsequently reduce cardiac toxicity and associated cardiovascular disease. PBRT minimizes radiation dose to the lung and secondary tissues resulting in reduced pulmonary toxicity and secondary malignancies, respectively. PBRT offers superior target homogeneity and lymphatic coverage possibly leading to a lower risk of disease recurrence. A phase 3 prospective randomized clinical trial is currently being conducted to evaluate the efficacy of PBRT compared to EBRT with photons in patients with stage II–III breast cancer. Patients over age 70 with favorable stage I breast cancer may omit adjuvant RT. Elderly patients who are candidates for WBI, APBI and chest wall irradiation can receive PBRT and enjoy the same aforementioned benefits with potentially less toxicities. PBRT also plays a role in disease palliation and definitive therapy in patients who are not surgical candidates. In the elderly population, screening tests, such as the Timed Up and Go and G-8, can help determine which patients are suitable candidates for PBRT.
format Online
Article
Text
id pubmed-8798667
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87986672022-02-02 The role of proton beam therapy in the management of elderly breast cancer patients Rich, Benjamin J. Asher, David Giap, Bosco Giap, Huan Transl Cancer Res Review Article Breast cancer is the most common noncutaneous malignancy in women. The prevalence increases with age such that nearly 7% of women in the United States over age 70 will be diagnosed with breast cancer. Radiation therapy (RT) is a standard component of the treatment course for women of all ages with breast cancer. RT is commonly encountered in the adjuvant setting for women with nonmetastatic disease, but also works for disease palliation in women with metastatic or recurrent disease. Different techniques for delivering RT for breast cancer include whole breast irradiation (WBI), accelerated partial-breast irradiation (APBI), and chest wall irradiation. Although these techniques often employ external beam radiation therapy (EBRT) delivered with photons, proton beam radiation therapy (PBRT) may also be used for each of these methods. Dosimetric breast cancer studies demonstrate clinical benefits of PBRT compared to photon EBRT. PBRT reduces the radiation dose delivered to the heart, particularly in women with left-sided breast cancer. This may subsequently reduce cardiac toxicity and associated cardiovascular disease. PBRT minimizes radiation dose to the lung and secondary tissues resulting in reduced pulmonary toxicity and secondary malignancies, respectively. PBRT offers superior target homogeneity and lymphatic coverage possibly leading to a lower risk of disease recurrence. A phase 3 prospective randomized clinical trial is currently being conducted to evaluate the efficacy of PBRT compared to EBRT with photons in patients with stage II–III breast cancer. Patients over age 70 with favorable stage I breast cancer may omit adjuvant RT. Elderly patients who are candidates for WBI, APBI and chest wall irradiation can receive PBRT and enjoy the same aforementioned benefits with potentially less toxicities. PBRT also plays a role in disease palliation and definitive therapy in patients who are not surgical candidates. In the elderly population, screening tests, such as the Timed Up and Go and G-8, can help determine which patients are suitable candidates for PBRT. AME Publishing Company 2020-01 /pmc/articles/PMC8798667/ /pubmed/35117960 http://dx.doi.org/10.21037/tcr.2019.07.40 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Review Article
Rich, Benjamin J.
Asher, David
Giap, Bosco
Giap, Huan
The role of proton beam therapy in the management of elderly breast cancer patients
title The role of proton beam therapy in the management of elderly breast cancer patients
title_full The role of proton beam therapy in the management of elderly breast cancer patients
title_fullStr The role of proton beam therapy in the management of elderly breast cancer patients
title_full_unstemmed The role of proton beam therapy in the management of elderly breast cancer patients
title_short The role of proton beam therapy in the management of elderly breast cancer patients
title_sort role of proton beam therapy in the management of elderly breast cancer patients
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798667/
https://www.ncbi.nlm.nih.gov/pubmed/35117960
http://dx.doi.org/10.21037/tcr.2019.07.40
work_keys_str_mv AT richbenjaminj theroleofprotonbeamtherapyinthemanagementofelderlybreastcancerpatients
AT asherdavid theroleofprotonbeamtherapyinthemanagementofelderlybreastcancerpatients
AT giapbosco theroleofprotonbeamtherapyinthemanagementofelderlybreastcancerpatients
AT giaphuan theroleofprotonbeamtherapyinthemanagementofelderlybreastcancerpatients
AT richbenjaminj roleofprotonbeamtherapyinthemanagementofelderlybreastcancerpatients
AT asherdavid roleofprotonbeamtherapyinthemanagementofelderlybreastcancerpatients
AT giapbosco roleofprotonbeamtherapyinthemanagementofelderlybreastcancerpatients
AT giaphuan roleofprotonbeamtherapyinthemanagementofelderlybreastcancerpatients